Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study

Rob Bielen, Özgür M Koc, Dana Busschots, Geert Robaeys, Bert Aertgeerts, Bert Vaes, Pavlos Mamouris, Catharina Mathei, Geert Goderis, Frederik Nevens

ABSTRACT

Objectives Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) have a major impact on mortality worldwide. Although effective treatments are available for both HBV and HCV infection, <50% of the patients are even diagnosed in Belgium. This study assessed the real-life testing—and diagnosis rate by general practitioners (GPs) in Flanders, Belgium.

Setting We assessed the testing rate for HBV and HCV in 48 primary care practices with electronic medical records linked into one central registry in Flanders, Belgium.

Participants The registry contains data of 440 140 patients over 20 years, which corresponds to 2.2% of the total Flemish population yearly. The primary care practices are distributed across Flanders and the patient population is representative for the distribution of age, gender and socioeconomic status at the community level.

Results Of 440 140 patients included in the registry, 7892 (1.8%) patients were screened for hepatitis B surface antigen (HBsAg) and 7206 (1.6%) for hepatitis C antibody (HCV Ab) of whom 369 (4.7%) and 163 (2.3%) tested positive, respectively. Of 14 059 patients with chronic liver enzyme elevation, 1112 (7.9%) and 1395 (9.9%) were tested for HBsAg and HCV Ab, respectively. There was no improvement in testing rates over time.

Conclusions This study demonstrates that real-life testing uptake for viral hepatitis B and C is suboptimal in the general practices in Flanders, even in patients with chronically elevated liver enzymes. As GPs play a crucial role in prevention, diagnosis and linkage to care, efforts and strategies to increase the testing uptake for HBV and HCV are urgently needed.

INTRODUCTION

Chronic viral hepatitis, mainly due to infections with hepatitis B virus (HBV) and hepatitis C virus (HCV), is a major global health problem. Worldwide, ~257 million people live with chronic HBV infection and 70–85 million people live with chronic HCV infection. The viral hepatitis pandemic is responsible for up to 1.4 million deaths annually, making it the seventh leading cause of mortality globally.

Treatment for chronic viral hepatitis has substantially improved over the last decades. Long-term suppression of HBV DNA levels can be achieved in all chronic HBV patients leading to an improvement in survival by preventing disease progression, and consequently liver cancer development. Direct-acting antivirals (DAAs) have revolutionised HCV treatment and can cure >90% of people with chronic HCV infection. Furthermore, with the availability of safe and effective vaccines to prevent HBV infection, the WHO developed a strategy towards eliminating viral hepatitis as a public health threat by 2030. Nevertheless, despite the progressive nature of the disease and the highly effective treatment, only a small proportion of patients with chronic viral hepatitis are diagnosed and are being treated.

In Flanders, Belgium, universal HBV vaccination strategy was already implemented in 1999, both for adolescents and newborns. Since 2008, the immunisation coverage for HBV is >95%. Nevertheless, due to migration, the mandatory notification rate of acute HBV infections remained stable from 2009 to
2015 (range 43–70 acute HBV cases). This was slightly lower in 2016 and 2017 (36 and 33 acute HBV cases, respectively). Prevalence studies of hepatitis B surface antigen (HBsAg) are outdated, but the prevalence of chronic HBV infection is estimated around 0.7%. Of an estimated 64 000 patients chronic HBV patients (95% CI 54 000 to 77 000), only 46% have been diagnosed. With recent advancements in treatment of chronic HBV infection, secondary prevention is possible. There is, however, no national plan to reduce the burden of HBV infection. Voluntary blood donors have been screened for HBV since 1972. HBV testing is also recommended during the first trimester of pregnancy. Healthcare workers are being tested and vaccinated, but no other testing strategies are recommended. Thus, improving testing uptake, diagnosis rate and linkage to care is necessary.

Concerning HCV infection, in 2015, there were an estimated 66 200 (95% CI 24 200 to 77 600) viremic HCV infections in Belgium, of which ~43% were diagnosed. To reach the 2030 targets of the WHO, diagnosis rates should have been increased by 10% each year beginning in 2016, to achieve a total of 3030 patients diagnosed annually by 2018. These targets have not been reached and are not being monitored. Government funded DAA therapy has been available since 2015 for patients with severe fibrosis or cirrhosis (≥F3 Metavir stage). Additionally, treatment became available to ≥F2 patients in 2017 and has become available for all patients in 2019.

Since 2014, there is a national hepatitis C plan, but none of the objectives concerning screening (including better informing general practitioners [GPs]) have been implemented. Given the significant clinical and economic burden of HCV, increasing detection rates is a priority. Several studies have shown a lack of screening for HCV in primary care in the USA but reports about HBsAg testing by GPs in real-life are absent. In Germany, in one prospective screening study, 85% of HBsAg and 65% of hepatitis C antibody (HCV Ab)-positive patients were previously undiagnosed in the primary care setting. Thus, monitoring of real-life testing and diagnosis rates is a gap in the current policy internationally. The goal of this observational study was to investigate the real-life testing and diagnosis rate of HBV and HCV in primary care in Flanders.

**MATERIALS AND METHODS**

**Study design**

This is an analysis of testing and diagnosis rate of HBV and HCV infection in around 50 primary care practices all linked in the INTEGO project. INTEGO is a registration network, which collects data from >100 GPs since 1994. These practices are distributed across Flanders, Belgium and the INTEGO patient population is representative for the Flemish population for age distribution, gender distribution and socioeconomic status at the community level. Every patient visiting these practices is eligible for inclusion within the registry. Data are collected yearly, and in 2015, 48 practices and 111 physicians cooperated for this project, which led to data collection of 123 261 patients, or ~2% of the Flemish population. In total, the INTEGO registry contains data of 440 140 patients over 20 years. Patient characteristics and diagnoses are encoded in the INTEGO registry using the International Classification of Primary Care (ICPC-2) codes by the participating GPs. Furthermore, all laboratory tests performed by GPs are included in the database. As such, the INTEGO registry contained 4 478 275 diagnoses and 44 747 161 laboratory results up to 2015. Data collection is regulated by an opting-out procedure, which is approved by the privacy commission in Belgium.

All patients registered in these practices between 1996 and 2015 were eligible for inclusion in this study. The laboratory test results concerning HBsAg and HCV Ab of all patients were collected using the INTEGO registry. After removal of duplicates, data were collected of all individuals ever tested for HBsAg and/or HCV Ab. Only two tests were being used across the different laboratories in Belgium, that is, Cobas Roche and Architect Abbott. A positive value for HBsAg and HCV Ab is defined by a cut-off value of 1.0, a negative value as <0.9 and borderline results between 0.9 and 1.0. For the purpose of this study, all tests ≥0.9 were withheld as possibly positive for both HBsAg and HCV Ab tests. The following baseline data were collected: year of birth, gender, HBsAg tests and dates of tests, HCV Ab tests and dates of tests, and all results of aspartate transaminase (AST) alanine aminotransferase (ALT) tests. Based on ICPC-2 codes registered by the GPs, data were collected on chronic alcohol abuse, diabetes, overweight and pregnancy. The dates of these registrations were also collected to collect information on time of these events versus HBV/HCV testing. HIV status was only collected of patients tested for HCV or HBV infection. Age at time of first testing of HBV or HCV infection was calculated. As HCV or HBV testing could also be performed in hospital settings, on referral of the GP, there could be an underestimation of these testing rates. Therefore, ICPC-2 codes on viral hepatitis were also added to minimise this risk.

For our second research question, we extracted all patients with chronically elevated liver enzymes, as defined by at least two AST or ALT elevations (>40 IU/L), 6 months apart. Patient characteristics were collected using the ICPC-2 codes with the same methodology.

**Objectives**

The primary endpoint of this study was to investigate the overall testing and diagnosis rate of HBV and HCV infection by primary care providers. As secondary endpoint, we analysed the testing and diagnosis rate of HBV and HCV in patients with elevated liver enzymes.

**Statistical analysis**

All analyses were performed using IBM SPSS V.24. Descriptive statistics of patient characteristics are presented: for continuous variables, means and SD, for categorical
variables proportions and percentages. Independent t-tests were used for the comparison of two continuous variables. When violating the assumptions for parametric tests (eg, normal distribution, homogeneity of variance), the Mann-Whitney U test was used instead. Categorical data were analysed with the \( \chi^2 \) test or Fisher’s exact test. Using the significant values (p<0.10), a multiple logistic regression model was executed. Model selection was done in a stepwise backward manner based on significance (p<0.05). Results were considered significant at the 0.05 level.

RESULTS

Overall testing for HBsAg and HCV Ab

In total, 10,684 patients were screened for HBsAg or HCV Ab between 1996 and 2015. The majority of patients tested were female: n=6500 (60.8%). Mean age at the time of the first test was 40±17 years. More specifically, 7892 were screened for HBsAg and 7206 for HCV Ab. Thus, out of the total of 440,140 patients in INTEGO registry, 1.8% and 1.6% of the patients were screened for HBV and HCV infection, respectively. In figure 1, the distribution of tested patients by age and gender is provided. Both for HBV and HCV infection, there is a clear overrepresentation of women in the reproductive age.

Characteristics of patients with positive HBsAg or HCV Ab

In tables 1 and 2, the association of patient characteristics on HBsAg and HCV Ab positivity in patients tested for these diseases is illustrated. Of the patients tested for HBsAg and HCV Ab, 4.7% and 2.3% tested positive, respectively. Only 42.3% of the HBsAg-positive individuals had at least one AST/ALT elevation. In multivariate regression analysis, HBsAg positivity was associated with chronically elevated liver enzymes (OR 1.60; 95% CI 1.23 to 2.07). Of the HBsAg-tested patients, 55.9% (4414/7892) were also screened for HCV, and 54.1% (4267/7892) for HIV infection. Moreover, HBsAg-positive patients were significantly less tested for HCV and HIV compared with HBsAg-negative patients.

Patients with elevated liver enzymes, older patients (mean age at time of testing 49 vs 42 years), people who use drugs and HIV-infected patients all had a higher chance of being HCV Ab positive in multivariate analysis. A total of 111 (68.1%) HCV-positive patients had at least one AST/ALT elevation. Again, only 61.3% (4414/7206) of the HCV-tested patients were also tested for HBsAg and only 54.1% (3902/7206) for HIV, and significantly less HCV Ab-positive patients were tested.

Testing for HBsAg and HCV Ab in patients with chronic liver enzymes elevation

There were 14,059 patients who had an elevation of AST or ALT ≥40 IU/L, at least twice, and 6 months apart. These patients were considered to have chronic liver enzymes elevation. The majority of these patients were male: n=9481 (67.4%). Mean age at the time of the first measurement of elevated liver enzymes was 55±16 years. Of these patients, only 1112 (7.9%) were tested for HBsAg and 1395 (9.9%) were tested for HCV Ab.

In figure 2, the evolution of testing is provided per time block of 5 years. There was no improvement in testing rates between these subgroups over time.

Of the patients who had at least once a chronic elevation of liver enzymes, 5.6% (305/5429) were tested for HBsAg and 7.6% (412/5429) for HCV Ab. In patients with chronic elevation and in addition two to four repeated AST/ALT elevations, 8.0% (493/6128) were screened for HBsAg and 9.8% (598/6128) for HCV Ab. Finally, in patients with more than five repeated AST/ALT elevations, 12.6% (314/2501) and 15.6% (385/2501) were screened for HBsAg and HCV Ab.

Patient characteristics associated with testing uptake for HBsAg and HCV Ab are demonstrated in tables 3 and 4. Patients with more than five repeated elevated liver tests were more likely to be screened for HBsAg, patients with HCV Ab positivity less likely. The same findings apply for

---

Figure 1  Number of patients (x-axis) tested for HBsAg (left) and HCV Ab (right), distributed by age (y-axis) and gender. HBsAg, hepatitis B surface antigen; HCV Ab, hepatitis C antibody.
testing for HCV Ab; patients with more than five repeated elevated liver tests were more likely to be screened, and patients with HBsAg positivity less likely. Patients were also more likely to be screened for HCV Ab when the patient was younger at the time of elevated liver enzymes. If these patients were screened for one of these infections, they were far more likely to be tested for other blood-borne viral infections as well.

**DISCUSSION**

In this study, we evaluate the real-life testing and diagnosis rate of HBV and HCV infection by GPs in Flanders, Belgium using the INTEGO registry. These data are representative for age and gender distribution and socioeconomic status in the Flemish community. Only 1.8% of the total INTEGO registry population were tested for HBsAg, and only 1.6% for HCV Ab between 1996 and 2015. Testing rates did not improve over time despite the development of very effective antiviral drugs. When testing was performed, it was most often done in women of reproductive age. HBsAg testing has been recommended in pregnant women for several years[^37]; however, HCV Ab testing has only been recommended for pregnant women with an increased risk of HCV infection.[^30] These higher testing rates in young women reflect the lack of an effective screening policy in Belgium, as the male gender is associated with a higher prevalence of viral hepatitis[^39,40].

To our knowledge, this is the first study internationally to assess the testing rate in routine practice for HBsAg by GPs. The low testing rate for HCV Ab in our study is in contrast with the findings of the recent hepatitis C report of the Belgian Institute of Health (WIV-ISP).[^39] Based on the number of serology requests to the National Institute for Health and Disability Insurance (RIZIV/INAMI) and extrapolated data of the permanent sample, an instrument designed by the InterMutualistisch Agentschap-Agence InterMutualiste (IMA-AIM),[^41] there was a yearly testing uptake of 2.5% for HCV and 33.4% of the Belgian population would have been tested during the last 9 years.[^39] At least our findings indicate that these high testing rates are not performed by GPs. Internationally, several studies assessed screening uptake for HCV in the general practice setting, and screening rates ranged from 4.3% to 15.8%.[^31–33,35] Even though these studies were conducted in large integrated healthcare systems or managed care organisations, many patients remained unscreened. This could be explained by the lack of knowledge about screening guidelines, the complexity of risk-based screening guidelines and reluctance to discuss socially undesirable behaviours[^42,43]. In another study in Australia,

| Table 1 | Relation of baseline characteristics to HBsAg-positive and HBsAg-negative patients |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Variable | Univariate analysis | | | | | | | Multivariate analysis |
| | (χ² and Student’s t-test) | | | | | | | (backward regression) |
| | HbsAg+ n=369 | HbsAg- n=7523 | P value | P value | OR | 95% CI | P value | OR | 95% CI |
| Elevated liver enzymes | | | | | | | | | |
| AST/ALT elevated at least once | 156 (42.3%) | 2678 (35.6%) | 0.010 | n.s. | | | | |
| AST/ALT elevated at least twice | 127 (34.4%) | 2022 (26.9%) | 0.002 | n.s. | | | | |
| AST/ALT elevated at least twice, >6 months | 75 (20.3%) | 1037 (13.8%) | 0.001 | <0.001 | 1.60 | 1.23 to 2.07 | | | |
| Age first HCV Ab or HbsAg test (y) (mean±SD) | 38±16 | 39±17 | 0.360 | | | | | |
| Gender (male) | 160 (43.4%) | 2826 (37.6%) | 0.028 | n.s. | | | | |
| Chronic alcohol abuse | 11 (3.0%) | 200 (2.7%) | 0.739 | | | | | |
| Drug abuse | 2 (0.5%) | 110 (1.5%) | 0.177 | | | | | |
| Diabetes | 43 (11.7%) | 915 (12.2%) | 0.807 | | | | | |
| Overweight | – | 15 (0.2%) | 0.641 | | | | | |
| Viral hepatitis test within pregnancy | 37 (10.0%) | 761 (10.1%) | 0.956 | | | | | |
| Coinfection | | | | | | | | |
| HIV positive | – | 9 (0.2%) | 0.999 | | | | | |
| HCV Ab positive | 1 (0.7%) | 66 (1.5%) | 0.525 | | | | | |
| Test HIV Ab (yes) | 98 (26.6%) | 4169 (55.4%) | <0.001 | | | | | |
| Test HCV (yes) | 144 (39.0%) | 4270 (56.8%) | <0.001 | | | | | |

ALT, alanine transaminase; AST, aspartate transaminase; HBsAg, hepatitis B surface antigen; HCV Ab, hepatitis C antibody; y, year. Significant values that were used in the regression model are highlighted in bold.
Gaps in knowledge of GPs on viral hepatitis ranged from natural history to diagnosis and treatment availability. Furthermore, GPs indicated in a national survey in New Zealand that insufficient training was a major barrier to treating HCV, and confidence rose significantly when being trained. Interestingly, GPs consistently underestimated the prevalence of HCV in their practice.

In patients with chronic liver enzyme elevation, testing uptake for HBV (7.9%) and HCV (9.9%) were low. Factors that could potentially induce AST/ALT elevation, such as alcohol abuse or diabetes (as a surrogate marker for non-alcoholic steatohepatitis) did increase the odds of being tested for viral hepatitis. Having multiple repeated elevated AST/ALT values increased the testing uptake. Nevertheless, in patients with more than five repeated elevated tests (>40 IU/L), still 85% were not tested. This gap should be closed as the HCV Ab prevalence was 10-fold higher in patients with elevated liver enzymes in primary care.

As testing was only performed on indication and not in all individuals, there was a high rate of HBsAg (4.7%) and HCV Ab (2.3%) positivity, far higher than the

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|-----------------------|
|          | HCV Ab+ n=163       | HCV Ab– n=7043        | P value | P value | OR | 95% CI |
| Elevated liver enzymes |                      |                      |         |         |    |        |
| AST/ALT elevated at least once | 111 (68.1%) | 2931 (41.6%) | <0.001 | 0.016 | 2.28 | 1.16 to 4.46 |
| AST/ALT elevated at least twice | 92 (56.4%) | 2223 (31.6%) | <0.001 | n.s. |
| AST/ALT elevated at least twice, >6 months | 66 (40.5%) | 1206 (17.1%) | <0.001 | 0.020 | 2.18 | 1.13 to 4.21 |
| Age first HCV Ab or HbsAg test (y) (mean±SD) | 49±18 | 42±18 | <0.001 | 0.023 | 1.02 | 1.00 to 1.04 |
| Gender (male) | 78 (49.9%) | 3032 (43.0%) | 0.231 |         |    |        |
| Chronic alcohol abuse | 5 (3.1%) | 212 (3.0%) | 0.999 |         |    |        |
| Drug abuse | 20 (12.3%) | 98 (1.4%) | <0.001 | <0.001 | 11.86 | 5.17 to 27.19 |
| Diabetes | 28 (17.2%) | 916 (13.0%) | 0.126 |         |    |        |
| Overweight | – | 5 (0.1%) | 0.999 |         |    |        |
| Viral hepatitis test within pregnancy | 6 (3.7%) | 440 (6.2%) | 0.179 |         |    |        |

ALT, alanine transaminase; AST, aspartate transaminase; HBsAg, hepatitis B surface antigen; HCV Ab, hepatitis C antibody; y, year. Significant values that were used in the regression model are highlighted in bold.

Figure 2  Evolution of testing rates over time for HBsAg (left) and HCV Ab (right). HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HCV Ab, hepatitis C antibody.
expected prevalence of HBV (0.7%) and HCV (0.87%) from previous seroepidemiological studies in the general Belgian population. In regard to HCV-positive patients, the presence of drug use or HIV positivity significantly increased the odds of HCV positivity. However, only a small proportion of the study population demonstrated these risk factors.

This study has several limitations. Although this registration network is representative for socioeconomic status at the community level, high-risk behaviour could still be underreported, as it is challenging to discuss sensitive personal behaviour, especially when this is not relevant to the medical care visit. Furthermore, the capacity to opt-out of the INTEGO registry potentially reduces the involvement of people at risk of hepatitis C participating in the system. The asymptomatic nature of viral hepatitis infection reduces the likelihood of people with the infection to request testing.

Due to the design of the study, no data on ethnicity and sexual preference were available. This is a concern as migration from countries with a high endemic prevalence of HBV infection is an important factor for HBV prevalence in developed countries. Also, only screening results of laboratory tests conducted by the GP are available, thus, there could be an underestimation of the number of tested patients if they were screened elsewhere. By using ICPC-2 codes for viral hepatitis, the risk of underreporting HBV-infected and HCV-infected patients was lowered.

This study clearly indicates the lack of an effective screening strategy for HBV and HCV in Belgium. Several studies have shown a lack of screening for HCV in primary care in the USA. In Germany, 85% of HBsAg and 65% of HCV Ab-positive patients were previously undiagnosed in the primary care setting. Simple interventions using electronic health record reminders and education can increase HCV screening both for risk-based screening guidelines and birth cohort screening. Importantly, in ~50% of the patients, screening was not performed for other blood-borne viruses, and this was even more explicit in patients who were positive for HBsAg or HCV Ab. This could be an underestimation if these patients were referred to hospitals for further workup, but since the transmission routes of these viruses are mostly the same, combined testing should be offered. In France, current screening guidelines have been simplified to address this issue, and combined testing should be offered to every adult at least once in a lifetime.

Simplifying screening guidelines in Belgium and educating or reminding GPs to screen for viral hepatitis will be crucial to increase the diagnosis rate.

**CONCLUSION**

This study demonstrates that real-life testing uptake for viral hepatitis B and C is low in the general practices in
Flanders, even in patients with chronically elevated liver enzymes. As GPs play a crucial role in prevention, diagnosis and linkage to care, efforts to increase uptake for testing for HBV and HCV should target GPs.

**Patient and public involvement**
No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. Encoded data were provided directly from the INTEGO registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry. There are no plans to disseminate the results of the research to study participants or the relevant patient registry.


REFERENCES

1. World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization, 2014.

2. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45–S57.

3. Global Burden of Disease and WHO/UNAIDS estimates. http://ihmeuw.org/3mps, http://ihmeuw.org (Accessed 2 Apr 2016).

4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370–98.

5. Papatheodoridis GV, Manolakopoulos S, Dushkevo G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:167–78.

6. Lawitz E, Sulkowski MS, Chai B, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–65.

7. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–21.

8. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/rimabtavir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983–92.

9. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88.

10. Sulkowski MS, Hezode C, Aluzaite K, Taar A, et al. German Check-Up 36+ Study Group. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol 2015;62:1256–64.

11. Truex C, Ell S, Goders G. Buntine F: 20 jaar huisartsenpraktijk in Vlaanderen (1994-2015). 2015. http://ima-aim.be/IMG/pdf/ poster_2015_final-2.pdf (Accessed 14 Jun 2018).

12. Smith BD, Aryal K, Braunschopf K, et al. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis 2015;60:1145–52.

13. Muyldermans G, Van Gucht S. Jaarrapport 2016: hepatitis C virus; Wetenschappelijk Instituut Volksgezondheid - Institution Scientifique de santé Publique (WIV-IISP). https://nrchm.wiv-isp.be/nl/ref_centra_labo/hepatitis/Rapporten/Rapport%20HCV%202016.pdf (Accessed 14 Jun 2018).

14. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007;110:941–56.

15. Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol 2017;217:B2–B12.

16. Muyldermans G, Van Gucht S. Jaarrapport 2016: hepatitis C virus; Wetenschappelijk Instituut Volksgezondheid - Institution Scientifique de santé Publique (WIV-IISP). https://nrchm.wiv-isp.be/nl/ref_central_labo/hepatitis/Rapporten/Rapport%20HCV%202016.pdf, ISBN 978-94-6292-613-7, 2015. Uitgeverij Acco D/2015/0543/61, ISBN 978-94-6292-629-0. https://nrchm.wiv-isp.be/nl/ref_central_labo/hepatitis/Rapporten/Rapport%20HCV%202016.pdf, ISBN 978-94-6292-629-0. (Accessed 21 Jun 2018).

17. Kallman JB, Arsalia A, Park V, et al. Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther 2009;29:1019–24.

18. Hewett A, Garg A, Meyer K, et al. Hepatitis C virus testing perspectives among primary care physicians in four large primary care settings. Health Promot Pract 2015;16:256–63.

19. Guigis M, Yan K, Bu YM, et al. General practitioners’ knowledge and management of viral hepatitis in the migrant population. Intern Med J 2012;42:497–504.

20. Johnson S, Aluzaite K, Taar A, et al. Identifying barriers to treatment of HCV in the primary care setting. Hepatol Int 2019;13:58–65.

21. Helser C, van Essen G, Frijling BD, et al. Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care. Br J Gen Pract 2012;62:e121–2.

22. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012;55:1047–55.
48. Ward JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. *Clin Liver Dis* 2013;17:1–11.

49. Orland JR, Wright TL, Cooper S. Acute hepatitis C. *Hepatology* 2001;33:321–7.

50. Bragg DA, Crowl A, Manlove E. Hepatitis C: A New Era. *Prim Care* 2017;44:631–42.

51. Chu JJ, Wörmann T, Popp J, *et al*. Changing epidemiology of hepatitis B and migration--a comparison of six Northern and North-Western European countries. *Eur J Public Health* 2013;23:642–7.

52. Litwin AH, Smith BD, Drainoni ML, *et al*. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. *Dig Liver Dis* 2012;44:497–503.

53. Konerman MA, Thomson M, Gray K, *et al*. Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. *Hepatology* 2017;66:1805–13.

54. Bottero J, Brouard C, Roudot-Thoraval F, *et al*. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. *Liver Int* 2016;36:1442–9.